Results overview: Found 7 records in 0.02 seconds.
Articles, 7 records found
Articles 7 records found  
1.
9 p, 1.3 MB Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies : exploratory analyses of the RAISE trial and validation in an electronic medical record data set / Grothey, Axel (Mayo Clinic) ; Yoshino, Takayuki (National Cancer Center Hospital East) ; Bodoky, Gyorgy (St László Hospital (Hongria)) ; Ciuleanu, Tudor Eliade (The Oncology Institute Prof Dr Ion Chiricută and Iuliu Hațieganu University of Medicine and Pharmacy) ; García-Carbonero, Rocío (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ; Van Cutsem, Eric (University Hospitals Leuven (Bèlgica)) ; Muro, Kei (Aichi Cancer Center Hospital) ; Mytelka, Daniel S. (Formerly of Eli Lilly and Company) ; Li, Li (Eli Lilly and Company) ; Lipkovich, Olga (Eli Lilly and Company) ; Hsu, Yanzhi (Eli Lilly and Company) ; Sashegyi, Andreas (Eli Lilly and Company) ; Ferry, David (Eli Lilly and Company) ; Nasroulah, Federico (Eli Lilly Argentina) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
In the RAISE trial, ramucirumab+leucovorin/fluorouracil/irinotecan (FOLFIRI) improved the median overall survival (mOS) of patients with previously treated metastatic colorectal cancer versus patients treated with placebo+FOLFIRI but had a higher incidence of neutropaenia, leading to more chemotherapy dose modifications and discontinuations. [...]
2018 - 10.1136/esmoopen-2018-000347
ESMO open, Vol. 3 (april 2018)  
2.
8 p, 590.0 KB Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study / Tabernero, Josep (Hospital Universitari Vall d'Hebron) ; Hozak, Rebecca R (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Yoshino, Takayuki (Division of Gastrointestinal Oncology/Digestive Endoscopy, National Cancer Center Hospital East, Chiba, Japan) ; Cohn, A. L. (Medical Oncology, Rocky Mountain Cancer Center/US Oncology, Denver, USA) ; Obermannova, R. (Masaryk Memorial Cancer Institute (Brno, República Txeca)) ; Bodoky, G. (St László Hospital (Hongria)) ; García-Carbonero, Rocío (Universidad Complutense de Madrid) ; Ciuleanu, Tudor Eliade (Medical Oncology, Prof. Dr. I. Chiricuţă Institute of Oncology, Cluj-Napoca, Romania) ; Portnoy, D. C. (Oncology, West Clinic, Memphis, USA) ; Prausová, J. (Department of Oncology and Radiotherapy, University Hospital Motol, Prague, Czech Republic) ; Muro, K. (Aichi Cancer Center Hospital) ; Siegel, R. W. (Laboratory for Experimental Medicine, Eli Lilly and Company, Indianapolis, USA) ; Konrad, R. J. (Laboratory for Experimental Medicine, Eli Lilly and Company, Indianapolis, USA) ; Ouyang, H. (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Melemed, Symantha A (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Ferry, David (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Nasroulah, F. (Oncology, Eli Lilly and Company, Argentina) ; Van Cutsem, E. (KU Leuven, Leuven, Belgium) ; Universitat Autònoma de Barcelona
The phase III RAISE trial (NCT01183780) demonstrated that the vascular endothelial growth factor (VEGF) receptor (VEGFR)-2 binding monoclonal antibody ramucirumab plus 5-fluororuracil, leucovorin, and irinotecan (FOLFIRI) significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo + FOLFIRI as second-line metastatic colorectal cancer (mCRC) treatment. [...]
2017 - 10.1093/annonc/mdx767
Annals of oncology, Vol. 29 (december 2017) , p. 602-609  
3.
11 p, 388.8 KB Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab / Arnold, D. (Instituto CUF de Oncologia (I.C.O.), Lisboa) ; Fuchs, C. S. (Internal Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA) ; Tabernero, Josep (Universitat Autònoma de Barcelona) ; Ohtsu, A. (Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan) ; Zhu, A. X (Massachusetts General Hospital (Boston)) ; Garon, E. B. (Hematology Oncology, David Geffen School of Medicine at UCLA Translational Research in Oncology-US Network, Santa Monica, USA) ; Mackey, J. R. (Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Canada) ; Paz Ares, L. (Hospital Universitario 12 de Octubre (Madrid)) ; Baron, A. D. (Division of Hematology Oncology, California Pacific Medical Center, San Francisco, USA) ; Okusaka, T. (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan) ; Yoshino, Takayuki (Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan) ; Yoon, H. H. (Division of Medical Oncology, Mayo Clinic, Rochester, USA) ; Das, M. (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Ferry, David (Oncology, Eli Lilly and Company, Bridgewater, USA) ; Zhang, Y (Oncology, Eli Lilly and Company, Bridgewater, USA) ; Lin, Y (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Binder, P. (Oncology, Eli Lilly and Company, Bridgewater, USA) ; Sashegyi, A.. (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Chau, Ian (Department of Medicine, Royal Marsden Hospital, Sutton, UK)
Ramucirumab, the human immunoglobulin G1 monoclonal antibody receptor antagonist of vascular endothelial growth factor receptor 2, has been approved for treating gastric/gastroesophageal junction, non-small-cell lung, and metastatic colorectal cancers. [...]
2017 - 10.1093/annonc/mdx514
Annals of oncology, Vol. 28 (september 2017) , p. 2932-2942  
4.
9 p, 1.1 MB Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab / Fuchs, Charles S. (Harvard Medical School) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Tomášek, Jiří (Masaryk University (Czech Republic)) ; Chau, Ian (Royal Marsden Hospital (Regne Unit)) ; Melichar, Bohuslav (Univerzity Palackeho a Fakultni nemocnice (Czech Republic)) ; Safran, Howard (Brown University Oncology Research Group (USA)) ; Tehfe, Mustapha A. (Centre Hospitalier de Montréal (Canada)) ; Filip, Dumitru (Spitalul Judetean de Urgenta (Romania)) ; Topuzov, Eldar (Northwest State Medical University na II Mechnikov) ; Schlittler, Luis (Hospital da Cida de Passo Fundo (Brasil)) ; Udrea, Anghel Adrian (Medisprof SRL (Romania)) ; Campbell, William (Hospital Herrera Llerandi (Guatemala)) ; Brincat, Stephen (Sir Anthony Mamo Oncology Centre (Malta)) ; Emig, Michael (Lilly Deutschland GmbH (Germany)) ; Melemed, Symantha A. (Lilly Corporate Center (USA)) ; Hozak, Rebecca R. (Lilly Corporate Center (USA)) ; Ferry, David (Lilly Corporate Center (USA)) ; Caldwell, C. William (Lilly Corporate Center (USA)) ; Ajani, Jaffer A. (The University of Texas MD Anderson Cancer Center (USA)) ; Universitat Autònoma de Barcelona
Angiogenesis inhibition is an important strategy for cancer treatment. Ramucirumab, a human IgG1 monoclonal antibody that targets VEGF receptor 2 (VEGFR2), inhibits VEGF-A, -C, -D binding and endothelial cell proliferation. [...]
2016 - 10.1038/bjc.2016.293
British Journal of Cancer, Vol. 115, Issue 8 (October 2016) , p. 974-982  
5.
6 p, 175.0 KB A metodologia de ensino com analogias (MECA) aplicada ao ensino de evolução : a árvore da vida de Charles Darwin / Marcelos, M. (FUNEC) ; Ferry, Alexandre da Silva (Universidade Federal de Minas Gerais)
Analogias são muito usadas no ensino de Ciências sem metodologia adequada, provocando equívocos de assimilação. Buscamos contribuir para o ensino de Ciências verificando, por meio da Metodologia de Ensino Com Analogias - MECA -, que relações estudantes de Ensino Médio estabelecem entre o veículo árvore e o alvo Evolução, tendo como base o texto da Árvore da Vida, de Darwin. [...]
2013
Enseñanza de las ciencias, Núm. Extra (2013) , p. 2114-2119 (Innovacions didàctiques)  
6.
7 p, 152.0 KB Concepções de estudantes acerca de analogias elabora¬das para o ensino de teorias atômicas : o modelo de dalton e a bola de bilhar / Ferry, Alexandre da Silva (Centro Universitário de Belo Horizonte. Faculdade Pitágoras) ; do Amaral, Silvia Eugênia (Brasil. Secretaria Municipal de Educação)
Neste artigo é relatado uma pesquisa realizada com 14 alunos da 1ª série do Ensino Médio da educação básica brasileira, na qual foram solicitados a descrever estruturalmente o modelo de átomo decorrente da teoria de John Dalton, do início do século XIX, além de citar alguma analogia conhecida para esse modelo atômico e a, principalmente, analisar uma comparação feita com uma bola de sinuca (ou bilhar). [...]
2013
Enseñanza de las ciencias, Núm. Extra (2013) , p. 1262-1268 (Innovacions didàctiques)  
7.
7 p, 136.9 KB Concepções de estudantes acerca de analogias elaboradas para o ensino de teorias atômicas : o modelo de Thomson e um pudim de ameixas / Ferry, Alexandre da Silva (Universidade Federal de Minas Gerais) ; Marcelos, M. F. (Centro Federal de Educação Tecnológica de Minas Gerais (Brasil))
2013
Enseñanza de las ciencias, Núm. Extra (2013) , p. 1269-1275 (Innovacions didàctiques)  

See also: similar author names
4 Ferry, David
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.